(NASDAQ:SNPS), NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Synopsys, Inc. (NASDAQ: SNPS) between December 4, 2024 and September 9, 2025, both dates inclusive (the “Class Period”), of the important December 30, 2025 lead plaintiff deadline. SO WHAT: If you […]

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Synopsys, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNPS GlobeNewswire December 05, 2025 NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Synopsys, Inc. (NASDAQ: SNPS) between December

NEW YORK CITY, NY / ACCESS Newswire / December 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Six Flags Entertainment Corporation ("Six Flags" or the "Company") (NYSE:FUN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by

NEW YORK CITY, NY / ACCESS Newswire / December 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Stride, Inc. ("Stride" or the "Company") (NYSE:LRN).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / December 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Synopsys, Inc. ("Synopsys" or the "Company") (NASDAQ:SNPS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

Calgary, Alberta–(Newsfile Corp. – December 5, 2025) – Trican Well Service Ltd. (TSX: TCW) (“Trican” or the “Company”) today announced the successful expansion and extension of its Revolving Credit Facility (“RCF”). Trican has entered into an amending agreement with its existing lending syndicate to expand the RCF from $150 million to $200 million and extend its

NEW YORK CITY, NY / ACCESS Newswire / December 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ:TLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

NEW YORK CITY, NY / ACCESS Newswire / December 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against WPP Plc ("WPP" or the "Company") (NYSE:WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 18,310 shares of its common stock to two newly-hired employees under Nektar's 2025 Inducement Plan. https://mma.prnewswire.com/media/1390052/Nektar_Logo_v1.jpg Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November

(Neo:GBFC),(Neo:GBFC.NE),(TSX:GCBD),(TSX:GCSC),(TSX:GCFE),(TSX:GDEP.B),(TSX:GDEP-B),(Neo:GBFD),(Neo:GBFD.NE),(Neo:GBFE),(Neo:GBFE.NE),(Neo:GBFF),(Neo:GBFF.NE),(Neo:GBLF),(Neo:GBLF.NE),(TSX:GDEP),(TSX:GDPY),(TSX:GDPY.B),(TSX:GDPY-B),(Neo:GIDY),(Neo:GIDY.NE),(TSX:GIQG),(TSX:GIQG.B),(TSX:GIQG-B),(Neo:GIQI),(Neo:GIQI.NE),(TSX:GIQU),(TSX:GIQU.B),(TSX:GIQU-B),(TSX:GIES),(TSX:GIGC),(Neo:GSIF),(Neo:GSIF.NE),(TSX:GCTB),(TSX:GUTB.U),(TSX:GUTB-U),(TSX:GCG),(TSX:GCG.A),(TSX:GCG-A), TORONTO, Dec. 05, 2025 (GLOBE NEWSWIRE) — Guardian Capital LP (“Guardian Capital”) announces the estimated annual non-cash year-end distributions (the “Non-Cash Distributions”) for the 2025 tax year for the ETF series of the Guardian Capital funds listed below (the “Guardian Capital ETFs”). Please note that these are estimated amounts as of November 14, 2025